Related Experiment Video
Updated: Jan 27, 2026
Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells
Published on: June 9, 2020
Aberrations in DNA repair pathways in cancer and therapeutic significances
Akira Motegi1, Mitsuko Masutani2, Ken-Ichi Yoshioka3
1Department of Radiation Genetics, Kyoto University Graduate School of Medicine, Yoshida Konoe, Sakyo-ku, Kyoto 606-8501, Japan.
Abstract:
Cancer cells show various types of mutations and aberrant expression in genes involved in DNA repair responses. These alterations induce genome instability and promote carcinogenesis steps and cancer progression processes. These defects in DNA repair have also been considered as suitable targets for cancer therapies. A most effective target so far clinically demonstrated is "homologous recombination repair defect", such as BRCA1/2 mutations, shown to cause synthetic lethality with inhibitors of poly(ADP-ribose) polymerase (PARP), which in turn is involved in DNA repair as well as multiple physiological processes. Different approaches targeting genomic instability, including immune therapy targeting mismatch-repair deficiency, have also recently been demonstrated to be promising strategies. In these DNA repair targeting-strategies, common issues could be how to optimize treatment and suppress/conquer the development of drug resistance. In this article, we review the extending framework of DNA repair response pathways and the potential impact of exploiting those defects on cancer treatments, including chemotherapy, radiation therapy and immune therapy.
Insights
DNA repair defects in cancer cells drive instability and progression. Targeting these defects, like homologous recombination repair, offers promising therapeutic strategies including chemotherapy, radiation, and immunotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cancer cells exhibit mutations and altered gene expression in DNA repair pathways, leading to genomic instability and disease progression.
- Defects in DNA repair mechanisms are recognized as critical targets for developing novel cancer therapies.
- Homologous recombination repair (HRR) deficiency, exemplified by BRCA1/2 mutations, presents a validated target, inducing synthetic lethality with poly(ADP-ribose) polymerase (PARP) inhibitors.
Purpose of the Study:
- To review the landscape of DNA repair response pathways in cancer.
- To explore the therapeutic potential of exploiting DNA repair defects across various treatment modalities.
- To discuss challenges and strategies for optimizing DNA repair-targeted cancer treatments and overcoming drug resistance.
Main Methods:
- Literature review of DNA repair pathways and their role in cancer.
- Analysis of current and emerging therapeutic strategies targeting DNA repair deficiencies.
- Examination of clinical applications of DNA repair-targeted therapies, including chemotherapy, radiation, and immunotherapy.
Main Results:
- Aberrant DNA repair is a hallmark of cancer, contributing to genomic instability and tumor evolution.
- Targeting DNA repair defects, such as HRR deficiency with PARP inhibitors, has shown significant clinical success.
- Immune therapies targeting mismatch-repair deficiency also represent a promising avenue for cancer treatment.
Conclusions:
- Exploiting DNA repair defects offers a versatile framework for developing innovative cancer therapies.
- Optimizing treatment regimens and addressing drug resistance are crucial for maximizing the efficacy of DNA repair-targeted strategies.
- Further research into DNA repair pathways will continue to unveil new therapeutic opportunities in oncology.
Related Concept Videos
02:25Overview of DNA Repair
Chemically...
02:25Overview of DNA Repair
01:08Nucleotide Excision Repair
02:27Base-pairing and DNA Repair
01:36Mismatch Repair
01:54Base Excision Repair
The first step of...